Targeting tyrosine kinases in cancer: The converging roles of cytopathology and molecular pathology in the era of genomic medicine

Cancer Cytopathology

Volumn 121, Issue 2, 2013, Pages 61-71

  Dumur, Catherine I ^a   Idowu, Michael O ^a   Powers, Celeste N ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cancer targeted therapies; Companion diagnostics; Cytopathology; Genomic medicine; Molecular diagnostics

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; PANITUMUMAB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; ASPIRATION CYTOLOGY; BREAST CANCER; CANCER GENETICS; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CYTODIAGNOSIS; CYTOPATHOLOGY; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; LIMIT OF DETECTION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR DIAGNOSIS; MOLECULAR MEDICINE; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SOMATIC MUTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; FORECASTING; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PATHOLOGY, MOLECULAR; PHARMACOGENETICS; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; UNITED STATES;

EID: 84876240173     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21225     Document Type: Review

References (107)

1. Kun M. New Instrument for the diagnosis of tumors. Mon J Med Sci. 1847;7:853-854.
2. Lebert H. Traite Pratique des Maladies Cancereuses et des Affections Curables Confondues Avec le Cancer. Paris, France: Chez J-B Bailliere; 1851.
3. Hajdu SI, Ehya H. Foundation of diagnostic cytology. Ann Clin Lab Sci. 2008;38:296-299.
4. Frable WJ. Integration of surgical and cytopathology: a historical perspective. Diagn Cytopathol. 1995;13:375-378. (Pubitemid 26044649)
5. Koss LG. Evolution in cervical pathology and cytology: a historical perspective. Eur J Gynaecol Oncol. 2000;21:550-554. (Pubitemid 32164816)
6. Frable WJ. Needle aspiration biopsy: past, present, and future. Hum Pathol. 1989;20:504-517. (Pubitemid 19164363)
7. Franzen S, Giertz G, Zajicek J. Cytological diagnosis of prostatic tumours by transrectal aspiration biopsy: a preliminary report. Br J Urol. 1960;32:193-196.
8. Long SR, Cohen MB. Classics in Cytology VII: Kun, Lebert, and early efforts at fine-needle aspiration biopsy. Diagn Cytopathol. 1996;14:182-183.
9. Webb AJ. Early microscopy: history of fine needle aspiration (FNA) with particular reference to goitres. Cytopathology. 2001; 12:1-6. (Pubitemid 32205334)
10. Beale LS. Results of the chemical and microscopical examination of solid organs and secretions. Examination of sputum from a case of cancer of the pharynx and the adjacent parts. Arch Med (Lond). 1861;2:44.
11. Long SR, Cohen MB. Classics in cytology. VI: The early cytologic discoveries of Lionel S. Beale. Diagn Cytopathol. 1993;9:595-598.
12. Greig ED, Gray AC. Note on the Lymphatic Glands in Sleeping Sickness. Br Med J. 1904;1:1252.
13. Martin HE, Ellis EB. Biopsy by needle puncture and aspiration. Ann Surg. 1930;92:169-181.
14. Stewart FW. The Diagnosis of Tumors by Aspiration. Am J Pathol. 1933;9:801-812.
15. Dufour H. Meningite sarcomateuse diffuse avec envahissement de la moelle et des racines. Cytologie positive et spéciale du liquide céphalorachidien. Rev Neuro (Paris). 1904;12:104-106.
16. Rindfleisch W. Ueber diffuse sarkomatose der weichen Hirn-und Ruckenmarkshaute mit charakteristischen Veranderungen der Cerebro- spinalflussigkeit. Dtsch Z Nervenheilkd. 1904;26:135-161.
17. Sanders WR. Cancer of the bladder. Fragments forming urethral plugs discharged in the urine. Concentric colloid bodies. Edinburgh Med J. 1864;10:273-274.
18. Coons AH, Jones RN. Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Biol Med. 1941; 47:200-202.
19. Coons AH, Kaplan MH. Localization of antigens in tissue cells. II. Improvements in a method for the detection of antigen by means of fluorescent antibody. J Exp Med. 1950;91:1-13.
20. Avrameas S, Uriel J. [Method of antigen and antibody labelling with enzymes and its immunodiffusion application]. C R Acad Sci Hebd Seances Acad Sci D. 1966;262:2543-2545.
21. Nakane PK, Pierce GB, Jr. Enzyme-labeled antibodies for the light and electron microscopic localization of tissue antigens. J Cell Biol. 1967;33:307-318.
22. DeLellis RA, Sternberger LA, Mann RB, et al. Immunoperoxidase technics in diagnostic pathology. Report of a workshop sponsored by the National Cancer Institute. Am J Clin Pathol. 1979;71: 483-488. (Pubitemid 9226855)
23. Nadji M. The potential value of immunoperoxidase techniques in diagnostic cytology. Acta Cytol. 1980;24:442-447. (Pubitemid 10059850)
24. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193-216. (Pubitemid 10191090)
25. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312:513-516. (Pubitemid 15182278)
26. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94:1593-1611. (Pubitemid 34212655)
27. Pegram M, Slamon D. Biological rationale for HER2/neu (cerbB2) as a target for monoclonal antibody therapy. Semin Oncol. 2000;27:13-19.
28. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994;9:1829-1838. (Pubitemid 24194147)
29. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001;28:13-19.
30. Lopes Cardoso P. Atlas of Clinical Cytology. Leiden, Targa: b.v.'s Hertogenbosch; 1976.
31. Donné AF. Cours de microsocopie complémentaire des études médicales. Paris: Chez J-B Ballière; 1844.
32. Lebert H. Physiologie pathologique ou recherches cliniques, experimentales et microscopiques. Paris: Chez J-B Ballière; 1845.
33. Gupta P, Baloch Z. Essential and Basic Concepts: Cytohistology of small tissue samples. Cambridge; 2011.
34. Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science. 1945; 101:519-520.
35. Crapanzano JP, Saqi A. Pitfalls in pulmonary cytopathology. Diagn Cytopathol. 2011;39:144-154.
36. Orell SR. Pitfalls in fine needle aspiration cytology. Cytopathology. 2003;14:173-182. (Pubitemid 36960403)
37. Daneshbod Y, Daneshbod K, Khademi B. Diagnostic difficulties in the interpretation of fine needle aspirate samples in salivary lesions: diagnostic pitfalls revisited. Acta Cytol. 2009;53:53-70.
38. Idowu MO, Powers CN. Lung cancer cytology: potential pitfalls and mimics - a review. Int J Clin Exp Pathol. 2010;3:367-385.
39. Stelow EB, Bardales RH, Stanley MW. Pitfalls in endoscopic ultrasound-guided fine-needle aspiration and how to avoid them. Adv Anat Pathol. 2005;12:62-73. (Pubitemid 40515794)
40. Sheahan P, Fitzgibbon J, O'Leary G, et al. Efficacy and pitfalls of fine needle aspiration in the diagnosis of neck masses. Surgeon. 2004;2:152-156. (Pubitemid 38807681)
41. Crapanzano JP, Zakowski MF. Diagnostic dilemmas in pulmonary cytology. Cancer. 2001;93:364-375. (Pubitemid 34023565)
42. Pedio G, Landolt-Weber U. Cytologic presentation of malignant mesothelioma in pleural effusions. Exp Cell Biol. 1988;56:211-216. (Pubitemid 18260946)
43. Beaty MW, Fetsch P, Wilder AM, et al. Effusion cytology of malignant melanoma. A morphologic and immunocytochemical analysis including application of the MART-1 antibody. Cancer. 1997;81:57-63. (Pubitemid 28275329)
44. Gherardi G, Marveggio C, Cola C, et al. Decisive role of immunocytochemistry in aspiration cytology of chordoma of the clivus: a case report with review of the literature. J Laryngol Otol. 1994; 108:426-430. (Pubitemid 24148425)
45. Silverman JF, Dabbs DJ, Gilbert CF. Fine needle aspiration cytology of adenosis tumor of the breast. With immunocytochemical and ultrastructural observations. Acta Cytol. 1989;33:181-187.
46. Dalquen P, Baschiera B, Chaffard R, et al. MIB-1 (Ki-67) immunostaining of breast cancer cells in cytologic smears. Acta Cytol. 1997;41:229-237. (Pubitemid 27172481)
47. Mayall F, Dray M, Stanley D, et al. Immunoflow cytometry and cell block immunohistochemistry in the FNA diagnosis of lymphoma: a review of 73 consecutive cases. J Clin Pathol. 2000; 53:451-457. (Pubitemid 30396467)
48. Bhanot P, Yang J, Schnadig VJ, et al. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature. Diagn Cytopathol. 2007;35:285-292. (Pubitemid 46652562)
49. Domanski HA, Akerman M, Rissler P, et al. Fine-needle aspiration of soft tissue leiomyosarcoma: an analysis of the most common cytologic findings and the value of ancillary techniques. Diagn Cytopathol. 2006;34:597-604. (Pubitemid 44298559)
50. Layfield LJ, Wallander ML. Diagnosis of gastrointestinal stromal tumors from minute specimens: Cytomorphology, immunohistochemistry, and molecular diagnostic findings. Diagn Cytopathol. 2012.
51. Balachandran I, Walker JW, Jr., Broman J. Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review. Diagn Cytopathol. 2010;38:213-216.
52. Hanley KZ, Birdsong GG, Cohen C, et al. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations. Cancer. 2009;117:279-288.
53. Shabaik A, Lin G, Peterson M, et al. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol. 2011;39:328-332.
54. Sobol RE, Astarita RW, Hofeditz C, et al. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst. 1987;79:403-407. (Pubitemid 17126586)
55. Rachwal WJ, Bongiorno PF, Orringer MB, et al. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer. 1995;72:56-64.
56. da Cunha SG, Saieg MA, Geddie W, et al. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol. 2011;119:80-91.
57. Billah S, Stewart J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 2011;119:111-117.
58. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6: 451-458.
59. Christopher BN, Cebulla CM, Wakely PE, Jr., et al. Molecular genetic testing of uveal melanoma from routinely processed and stained cytology specimens. Exp Eye Res. 2011;93:720-725.
60. Shen-Gunther J, Yu X. HPV molecular assays: defining analytical and clinical performance characteristics for cervical cytology specimens. Gynecol Oncol. 2011;123:263-271.
61. Aaronson SA. Growth factors and cancer. Science. 1991;254: 1146-1153. (Pubitemid 21917439)
62. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357: 2040-2048. (Pubitemid 350106711)
63. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537. (Pubitemid 41540110)
64. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182. (Pubitemid 17231334)
65. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648. (Pubitemid 29415219)
66. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344: 783-792. (Pubitemid 32222155)
67. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345. (Pubitemid 38944402)
68. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697-4705.
69. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357: 2040-2048. (Pubitemid 350106711)
70. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311. (Pubitemid 39209661)
71. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056. (Pubitemid 32267975)
72. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
73. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954. (Pubitemid 34716871)
74. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404. (Pubitemid 37452745)
75. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305-2315.
76. Honecker F, Wermann H, Mayer F, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol. 2009;27:2129-2136.
77. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105:3041-3046. (Pubitemid 351723664)
78. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
79. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-1664. (Pubitemid 46797944)
80. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353:123-132. (Pubitemid 41058344)
81. Goerner M, Seiwert TY, Sudhoff H. Molecular targeted therapies in head and neck cancer-an update of recent developments-. Head Neck Oncol. 2010;2:8.
82. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-5909.
83. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-379. (Pubitemid 351171687)
84. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304:1812-1820.
85. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-5712.
86. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753-762.
87. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007;97:1139-1145. (Pubitemid 47587019)
88. Yang H, Higgins B, Kolinsky K, et al. Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. Cancer Res. 2012;72:779-789.
89. Richman SD, Chambers P, Seymour MT, et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst). 2011;34:61-66.
90. Symmans WF, Ayers M, Clark EA, et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003;97:2960-2971. (Pubitemid 36676249)
91. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010;12:425-432.
92. Milbury CA, Li J, Liu P, et al. COLD-PCR: improving the sensitivity of molecular diagnostics assays. Expert Rev Mol Diagn. 2011; 11:159-169.
93. Whitcombe D, Theaker J, Guy SP, et al. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol. 1999;17:804-807. (Pubitemid 29365111)
94. Neumann J, Zeindl-Eberhart E, Kirchner T, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205:858-862.
95. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6:201-205.
96. Li J, Wang L, Mamon H, et al. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008;14:579-584. (Pubitemid 351655208)
97. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7: 169-181.
98. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2:e73.
99. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008;26:983-994. (Pubitemid 351398092)
100. Okayama N, Nishioka M, Hazama S, et al. The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues. Jpn J Clin Oncol. 2011;41:165-171.
101. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations. Clin Cancer Res. 2012;18:1167-1176.
102. Gundry M, Li W, Maqbool SB, et al. Direct, genome-wide assessment of DNA mutations in single cells. Nucleic Acids Res. 2011.
103. Ladd AC, O'Sullivan-Mejia E, Lea T, et al. Preservation of fineneedle aspiration specimens for future use in RNA-based molecular testing. Cancer Cytopathol. 2011;119:102-110.
104. da Cunha SG, Liu N, Tsao MS, et al. Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards: is this the tool for biobanking cytological samples in the molecular era? Cancer Cytopathol. 2010;118:450-456.
105. Saieg MA, Geddie WR, Boerner SL, et al. The use of FTA cards for preserving unfixed cytological material for high-throughput molecular analysis. Cancer Cytopathol. 2012;120:206-214.
106. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007; 39:347-351. (Pubitemid 46328493)
107. Elliott AM, Radecki J, Moghis B, et al. Rapid Detection of the ACMG/ACOG-Recommended 23 CFTR Disease-Causing Mutations Using Ion Torrent Semiconductor Sequencing. J Biomol Tech. 2012;23:24-30.